Rossie, Simona MD

  • Hepatology
Featured image for “Rossie, Simona MD”

Suite: 200

Dr. Simona Rossi is Associate Chairman of the Division of Hepatology for Einstein Healthcare Network in Philadelphia, Pennsylvania. Board certified in Internal Medicine, Gastroenterology and Transplant Hepatology, Dr. Rossi has been a co-investigator for numerous clinical trials, including a NIH-funded study of drug-induced liver disease, liver injury resulting from dietary supplements, and other research projects pertaining to treatment for hepatitis C and cirrhosis of the liver. She holds national appointments on the Women’s Representative Committee of the American Association for the Study of Liver Diseases (AASLD) and is an AASLD representative to the Gastroenterology Women’s Coalition. Born in Milano, Italy, Dr. Rossi received her medical education from Georgetown University School of Medicine, following her undergraduate at College of the Holy Cross in Worcester, Massachusetts, where she graduated Cum Laude. She completed fellowships in Gastroenterology and Hepatology and Transplant Hepatology at Thomas Jefferson University Hospital, where she subsequently held numerous appointments, including Assistant Professor of Medicine for the Division of Gastroenterology and Hepatology, as well as Medical Director of the Kimmel Cancer Center-Liver Tumor Center. In 2013, Dr. Rossi moved to her current position at Einstein Healthcare Network. Her recent honors include the Dean’s Team Achievement Award for the Liver Transplant Team at Thomas Jefferson University Hospital, as well as the Dean’s Citation for the Advancement of Education at Jefferson Medical College. Dr. Rossi has also contributed to a variety of peer-reviewed clinical research publications, most recently on the topics of drug-induced liver injury and the potential future in the treatment of Hepatitis C. Dr. Rossi has participated in numerous national lectures on Gastroenterology and Hepatology. She is currently participating in a number of government-funded clinical trials, including a randomized, open-label, multicenter controlled study to assess safety and efficacy of ELAD in subjects with acute alcoholic hepatitis. – See more at: